company tower banner
Chenland Nutritionals Company Logo
ClamBP™ utilizes marine protein peptides prepared by our eco-friendly patented bionic enzymolysis technology of Philippine clams. Traceability is guaranteed through strict quality control throughout the production process.

Ingredient Name: Marine Peptide

Ingredient Origin: Animal Origin, Marine Origin, Natural Origin

Labeling Claims: Environmentally Friendly, Halal, Kosher

Certifications & Compliance: Generally Recognized As Safe (GRAS), Halal, Kosher

    Knowde Enhanced TDS

    Identification & Functionality

    Ingredient Name
    Food Ingredients Functions
    Pharma & Nutraceuticals Functions
    Ingredients
    Clam Extract, Marine Peptide

    Features & Benefits

    Product Background
    1. The Clams (R. philippinarum) belong to the Veneridae clam family and is widely distributed on the coasts of China, Korea, Japan, America, and Spain.
    2. It is considered a delicacy in Asian countries and utilized as medicine to strengthen organs, lower blood sugar, and promote the blood circulation with a history of usage over 1,000 years.
    3. We extracted the peptides through our patented Enzytideᵀᴹ technology, which is an eco-friendly and targeted enzymolysis process to break down the protein into small peptide and increase bioactivity.
    Mechanism of Action
    • ClamBP™ can help to reduce systolic and diastolic blood pressure, relieve kidney damage by specifically inhibiting the expression of RAS-related pathway factors.
    • It regulates concentration of key biomarkers such as ACE\ACE2\Ang-II in blood and kidney tissues thereby protecting overall kidney function and lowering blood pressure.

    ClamBP™ - Mechanism of Action

    Product Highlights
    • Clinically proven
    • Supports for kidney function
    • Helps to stabilize blood pressure
    • Established mechanism of action
    • Good water solubility and stability
    • Kosher and Halal
    Health Benefits
    • Hypertension relief
    • Helps improve the kidney health with hypertension
    • Helps improve the glomerular structure changes, inflammation, and collagen deposition
    Absorption

    Full absorption, no significant decrease in ACE inhibition rate in stomach and gut

    Mechanism of Action
    1. ClamBPᵀᴹ can help to reduce systolic and diastolic blood pressure, relieve kidney damage by specifically inhibiting the expression of RAS-related pathway factors.
    2. It regulates concentration of key biomarkers such as ACE\ACE2\Ang-II in blood and kidney tissues thereby protecting overall kidney function and lowering blood pressure.

    Applications & Uses

    Food & Nutrition Applications
    Use Level
    Dosage : 500 - 1000 mg
    Dosage and Forms
    • ClamBPᵀᴹ can be used in capsule, tablet, beverage, gummy, and more.
    • It can also be used as a single ingredient or formulated with other nutrients.

    Dosage

    Amount per serving % Daily Value
    ClamBPᵀᴹ 500 mg

    Food & Beverage : 1 serving
    Dietary Supplement : 2 servings
    Medical food : 4 servings

    Target Populations

    • People with hypertension along with kidney damage
    • People with high blood pressure
    • People with high blood lipid
    • Sub-healthy population with metabolic problems

    Properties

    Solubility
    Typical Properties
    ValueUnitsTest Method / Conditions
    Peptides Content72.0%
    Molecular Weightmax. 1000Dalton

    Regulatory & Compliance

    Regulatory Status

    Food Ingredient in Asia, Europe, North America, GRAS (in the process).

    Technical Details & Test Data

    Clinical Studies on

    We have run an open-label human clinical study with 30 adults aged between 18-65 years old and with mild to moderate blood hypertension.

    The subjects received the 1,800 mg/day ClamBPᵀᴹ for 6 weeks.

    ClamBP™ - Clinical Studies On

    Figure 1 : Significant reduction in blood pressure within 6 weeks. No adverse events were observed during the study and no changes were found in the hematological analysis.

    Clinical Studies on

    ClamBP™ - Clinical Studies On

    Fig 2 : Reduced the concentration of ACE activity in the kidney and increase the
    concentration of ACE2 in SHRs

    Clinical Studies on

    ClamBP™ - Clinical Studies On

    Fig 3 : Regulate the blood lipid by reducing the concentration of serum total cholesterol (TC), Triglyceride (TG), Low-density lipoprotein (LDL) and increasing the concentration of high-density lipoprotein (HDL).

    Efficacy in Hypertension

    Systolic pressure reduced from 144 mmHg at the start of the trial to 135 mm Hg after 6 weeks, diastolic pressure from 88 mm Hg to 82 mmHg.

    Safety & Health

    Safety

    It was more than 3,330 mg/kg in NOAEL rats, is equivalent to a clinical dosage of 200 g.